姜浩,王智,史震涛,刘坤,唐强

• 1:北京大学首钢医院心血管内科

摘要(Abstract)：

目的评估药物洗脱球囊(DEB)在冠心病患者冠状动脉原位病变中应用的临床效果。方法回顾性分析2017年5月至2020年5月于北京大学首钢医院心血管内科住院的100例冠心病患者,冠状动脉造影(CAG)检查存在冠状动脉原位病变且行DEB治疗,并在术后4～9个月复查CAG。根据定量冠状动脉造影(QCA)测定狭窄病变的长度、直径以及面积等。主要观察指标为晚期管腔丢失以及晚期净获得,次要观察指标为死亡、靶血管血运重建、非靶血管血运重建、急性心肌梗死、心力衰竭以及出血等。结果入选患者中男74例,女26例,平均年龄(60.1±9.3)岁。共干预病变112处,其中直径≥2.8 mm病变21处(18.8%),急性完全闭塞病变15处(13.4%),分叉病变20处(17.9%)。术前病变长度(13.79±6.26)mm,参考血管直径为(2.36±0.65)mm。术前和术后即刻最小管腔直径分别为(0.80±0.46)mm和(1.59±0.46)mm。无患者在DEB治疗时出现C型及以上夹层。随访期间无患者死亡。2例患者在1个月随访时接受非靶血管血运重建治疗,累计12例患者在6个月随访时接受非靶血管血运重建治疗。随访时最小管腔直径为(1.60±0.46)mm,晚期管腔丢失为(0.016±0.360)mm,晚期净获得为(0.81±0.51)mm。结论冠状动脉原位病变中应用DEB的短期安全性和有效性令人满意。

关键词(KeyWords)： 药物洗脱球囊;冠状动脉原位病变;晚期管腔丢失;安全性;有效性

Abstract:

Keywords:

基金项目(Foundation): 中国心血管健康联盟苏州工业园区研究院（CCA20161201）

作者(Author): 姜浩,王智,史震涛,刘坤,唐强

参考文献(References)：

• [1]Scheller B,Speck U,Abramjuk C,et al.Paclitaxel balloon coating,a novel method for prevention and therapy of restenosis.Circulation,2004,110(7):810-814.
• [2]Unverdorben M,Kleber FX,Heuer H,et al.Treatment of small coronary arteries with a paclitaxel-coated balloon catheter.Clin Res Cardiol,2010,99(3):165-174.
• [3]Unverdorben M,Kleber FX,Heuer H,et al.Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study:are lesions clinically stable from 12 to36months?Euro Intervention,2013,9(5):620-628．
• [4]Mathey DG,Wendig I,Boxberger M,et al.Treatment of bifurcation lesions with a drug-eluting balloon:The PEPCADV (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial.Euro Intervention,2011,7(suppl K):K61-K65.
• [5]Alfonso F,Scheller B.State of the art:balloon catheter technologies drug-coated baloon.Euro Intervention,2017,13(6):680-695.
• [6]陈韵岱，王建安，刘斌，等.药物涂层球囊临床应用中国专家共识.中国介入心脏病学杂志，2016,24(2):61-67.
• [7]Scheller B,Hehrlein C,Bocksch W,et al.Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.N Engl JMed,2006,355(20):2113-2124.
• [8]Latib A,Colombo A,Castriota F,et al.A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxeleluting stent in small coronary vessels:the BELLO (Balloon Elution and Late Loss Optimization) study.J Am Coll Cardiol,2012,60(20):2473-2480.
• [9]Naganuma T,Latib A,Sgueglia GA,et al.A 2-year followup of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with apaclitaxel-eluting stent in small coronary vessels the BELLO study.Int J Cardiol,2015,184:17-21.
• [10]Jeger RV,Farah A,Ohlow MA,et al.Long-term effi cacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2):3-year followup of a randomised,non-inferiority trial.Lancet,2020,396(10261):1504-1510.
• [11]Jeger RV,Eccleshall S,Wan Ahmad WA,et al.Drug-Coated balloons for coronary artery disease third report of the international DCB consensus group.JACC Cardiovasc Interv,2020,13(12):1391-1402.
• [12]刘坤，王智，史震涛，等.药物涂层球囊在冠状动脉原位大血管病变中的应用效果评价.中国循证心血管医学杂志，2020,12(2):210-213.
• [13]Yu X,Ji F,Xu F,et al,Treatment of large de novo coronary lesions with paclitaxel-coated balloon only:results from a Chinese institute.Clin Res Cardiol,2019,108(3):234-243.
• [14]Liu Y,Zhang YJ,Deng LX,et al.12-Month clinical results of drugcoated balloons for de novo coronary lesion in vessels exceeding 3.0 mm.Int J Cardiovasc Imaging,2019,35(4):579-586.
• [15]Vos NS,Fagel ND,Amoroso G,et al.Paclitaxel-coated balloon angioplasty versus drug eluting stent in acute myocardial infarction:the REVELATION randomized trial.JACCCardiovasc Interv,2019,12(17):1691-1699.
• [16]Jim MH,Lee MK,Fung RC,et al.Six month angiographic result of supplementary paclitaxel-eluting balloon deployment to treat side branch ostium narrowing(SARPEDON).Int JCardiol,2015,187:594-597.
• [17]Berland J,Lefevre T,Brenot P,et al.DANUBIO-a n e w drug-eluting balloon for the treatment of side branches in bifurcation lesions:six-month angiographic follow-up results of the DEBSIDE trial.Euro Intervention,2015,11(8):868-876.
• [18]Kleber FX,Rittger H,Ludwig J,et al.Drug eluting balloons as stand alone procedure for coronary bifurcational lesions:results of the randomized multicenter PEPCAD-BIF trial.Clin Res Cardiol,2016,105(7):613-621.